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Abstract 
Intraperitoneal metastasis is a common occurrence and is usually involved in the poor prognosis of 
ovarian cancer. Its specific metastatic pattern implies that certain indispensable microenvironmental 
factors secreted in the peritoneal cavity can direct metastatic ovarian cancer cells to permissive niches for 
secondary lesion formation. However, the underlying molecular mechanisms are ill defined. Herein, we 
report that GRO-α and IL-8 are predominately upregulated in culture media derived from either normal 
or cancerous omenta and are associated with increased ovarian cancer aggressiveness.  
Methods: OCM was established from culture medium of fresh human omental tissues. Primary and 
metastatic ovarian cancer cell lines were generated from human tumor tissues and verified by specific 
antibodies. The functional roles of GRO-α, IL-8, and their specific receptor CXCR2 were examined by 
neutralizing antibodies, shRNA gene knockdown, CRISPR/Cas9 gene knockout and pharmaceutical 
CXCR2 inhibitor SB225002. The oncogenic properties of ovarian cancer cells were examined by in vitro 
and in vivo mouse models.  
Results: Both GRO-α and IL-8 can activate TAK1/NFκB signaling via the CXCR2 receptor. Intriguingly, 
TAK1/NFκB signaling activity was higher in metastatic ovarian cancer cells; this higher activity makes 
them more susceptible to OCM-induced tumor aggressiveness. Treatment of ovarian cancer cells with 
GRO-α and IL-8 neutralizing antibodies or ablation of CXCR2 by shRNA gene knockdown, CRISPR/Cas9 
gene knockout, or CXCR2 inhibitor SB225002 treatment significantly attenuated TAK1/NFκB signaling 
and decreased in vitro and in vivo oncogenic and metastatic potential, suggesting CXCR2 plays a key role 
in the GRO-α and IL-8-governed metastatic spreading of ovarian cancer cells in the intraperitoneal cavity.  
Conclusion: This study highlights the significance of GRO-α and IL-8 as the key chemokines in the 
peritoneal tumor microenvironment and suggests the utility of targeting their receptor CXCR2 as a 
potential target-based therapy for peritoneal metastases of ovarian cancer. 
Key words: chemokines, IL-8, GRO-α, CXCR2, NFκB signaling, ovarian cancer 
Introduction 
Unlike other human cancers, transcoelomic 
metastasis is the most common route of cancer spread 
in ovarian cancer [1]. Clinical evidence indicates that 
ovarian cancer with peritoneal metastases is usually 
accompanied with poor prognosis [2, 3]. Within the 
peritoneal cavity, omentum is one of the most 
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preferential tissues for metastatic ovarian cancer 
seeding. However, this tissue is rarely studied, and 
the underlying molecular mechanism for the 
interaction between the omental microenvironment 
and metastatic ovarian cancer cells in tumor 
colonization remains obscure. Emerging evidence has 
suggested that chemokines play an active role in 
reprogramming the tumor microenvironment and 
promoting cancer cell dissemination. For example, 
omental adipocytes secrete numerous growth factors 
and hormones, such as IL-6, IL-8, MCP-1, TIMP-1 and 
adiponectin, to promote tumor growth and cancer cell 
aggressiveness in various human cancers [4, 5], 
suggesting the importance of chemokine-induced 
oncogenic alteration of the tumor microenvironment 
in promoting omental metastasis.  
In addition to the effects of the tumor 
microenvironment, malignant cells intrinsically alter 
their behaviors and qualities to adapt to microenvir-
onmental reprogramming during tumor development 
and progression. It is hypothesized that metastatic 
cancer cells escaping from primary tumor sites 
acquire genetic and epigenetic alterations to resist 
stresses and traverse boundaries [6, 7]. This 
hypothesis implies that metastatic cancer cells are 
considered more aggressive than primary tumor cells 
due to their gain of tumorigenic capacities [6, 7]. 
Numerous studies have documented that nuclear 
factor-kappa B (NFκB) deregulation is favorably 
associated with cancer progression via its promotion 
of cancer cell proliferation and metastatic capacity [8, 
9]. Indeed, our previous report showed that aberrant 
phosphorylation of transforming growth factor 
(TGF)-β-activating kinase 1 (TAK1) at serine 412 is 
critically involved in the activation of NFκB signaling 
and is associated with ovarian cancer cell 
aggressiveness [10]. These findings suggest that 
TAK1/NFκB signaling plays a vital role in ovarian 
cancer metastasis.  
In this study, we established omentum 
conditioned medium (OCM) as a model to study the 
interplay between metastatic ovarian cancer cells and 
omental tumor microenvironment during cancer cell 
colonization. We identified interleukin 8 (IL-8/ 
CXCL8) and growth related oncogene-alpha 
(GRO-α/CXCL1) are the key chemokines in normal or 
cancerous OCMs stimulate the metastatic properties 
of ovarian cancer cells through activation of 
TAK1/NFκB signaling cascade via CXCR2. Our 
research provides a scientific basis for the importance 
of chemokines in the tumor microenvironment for the 
metastatic progression of ovarian cancer. Their related 
receptors and signaling may be potential therapeutic 
targets for impeding ovarian cancer metastasis.  
Materials and Methods  
Cell lines and human clinical samples 
The human ovarian high-grade serous cancer 
cell line OVCA433 (advanced serous papillary 
cystadenocarcinoma) was kindly provided by 
Professor G. S. W. Tsao, Department of Anatomy, The 
University of Hong Kong, and ES-2 (verified as high 
grade serous subtype [11]). HEK293 cells were 
purchased from American Type Culture Collection 
(ATCC, Rockville, MD, USA). The human ovarian 
adenocarcinoma cell lines OVSAHO (JCRB1046) and 
OVKATE (JCRB1044) (Stage 3c adenocarcinoma) were 
purchased from Japanese Collection of Research 
Bioresources Cell Bank (JCRB Cell Bank, Japan). 
Another two high grade ovarian adenocarcinoma cell 
lines, SKOV3 (ATCC) and A2780cp (cisplatin cell line 
derived from A2780), were kindly provided by Prof. 
Benjamin Tsang, Department of Obstetrics and 
Gynaecology, University of Ottawa. The immortal-
ized human ovarian surface epithelium (HOSE) cell 
line HOSE 96-9-18 was kindly provided by Prof. 
George Tsao, Department of Anatomy, University of 
Hong Kong. The cells were maintained in Dulbecco’s 
modified Eagle’s medium or MCDB 105 and medium 
199 (1:1) (Invitrogen Life Technologies, Carlsbad, CA, 
USA) supplemented with 10% (v/v) fetal bovine 
serum (Invitrogen, Gibco, Gaithersburg, MD, USA) 
and 100 U/mL penicillin/streptomycin (Invitrogen 
Life Technologies, Carlsbad, CA, USA) in an 
incubator at 37°C with a humidified atmosphere of 
5% CO2 and 95% air. All cell lines were authenticated 
by in-house Short Tandem Repeat (STR) DNA 
profiling and mycoplasma tests. Primary ovarian 
surface epithelium (OSE) cancer cells were prepared 
from fresh tumors collected from Queen Mary 
Hospital, The University of Hong Kong. The origins 
of all primary OSE cells were verified by immuno-
fluorescence analysis using pan-cytokeratin (pan-CK) 
(1:1000; Dako, Denmark), cytokeratin 7 (CK7) (1:1000; 
Dako), and vimentin (Vim) (1:1000; Dako) staining as 
well as by flow cytometric analysis (BD FACSAria 
SORP) using APC-CD45 (BioLegend, San Diego, CA, 
USA) or CA125 (Abcam, UK) antibodies to analyze 
the percentages of CA125+CD45- cells in primary OSE 
cancer cells. All primary OSE cancer cells were 
maintained in MCDB 105 and medium 199 (1:1). The 
OCM was prepared using fresh human omental 
tissues collected from surgeries performed at Queen 
Mary Hospital, University of Hong Kong. After each 
sample was washed and dissected into small pieces, 
approximately 3 g of each omental sample was 
incubated in 45 mL MCDB 105 and medium 199 (1:1) 
for 24 h. After repeated filtering and centrifugation, 
the supernatant was stored at 4°C for future use.  
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Reagents  
The TAK1 inhibitor, (5z)-7-oxozeaenol, was 
purchased from Sigma (Sigma Chemical Co., St. 
Louis, MO, USA). The CXCR2 chemokine receptor 
antagonist SB225002 was purchased from Selleck 
(Selleck Chemical, Houston, USA), and all 
recombinant human chemokines (CXCL7, GRO-α and 
IL-8) were obtained from Novus (NOVUS, Littleton, 
CO).  
RNA extraction and real-time quantitative 
reverse transcription PCR (QPCR) analysis 
Total RNA was extracted using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instruc-
tions. Complementary DNA (cDNA) was synthesized 
using a reverse transcription reagent kit (Applied 
Biosystems, Foster City). The expression levels of 
GRO-α and IL-8 were evaluated by QPCR in an ABI 
PRISM 7500 system (Applied Biosystems) using 
Taqman gene expression assays: human GRO-α 
(Assay ID: Hs00236937_m1) and human IL-8 (Assay 
ID: APTZ9ZR). Human GAPDH (Assay ID: 
Hs02786624_g1) was used as an internal control.  
Western blot analysis  
Proteins lysates were isolated from cells using 
cell lysis buffer (Cell Signaling Technology) 
containing protease inhibitor cocktail (Roche) and 
phenylmethylsulfonyl fluoride (Sigma Chemical Co.). 
Samples were separated by 10% SDS-PAGE and 
transferred to polyvinylidene difluoride (PVDF) 
membranes. The membranes were blotted with 5% 
skimmed milk and subsequently probed overnight at 
4°C with primary antibodies specific for anti-p-TAK1 
(Ser412), anti-TAK1, anti-p-IKKα/β (Ser180/181), 
anti-IKKα/β, anti-p-IκBα, anti-IκBα (Cell Signaling, 
Beverly, MA, USA) and anti-β-actin (Sigma-Aldrich, 
St. Louis, MO, USA) and then incubated with 
horseradish peroxidase-conjugated goat anti-rabbit or 
anti-mouse secondary antibody (Amersham, Uppsala, 
Sweden). Immunodetection was performed with 
enhanced chemiluminescence reagent solution 
(AmershamTM ECLTM) and visualized by X-ray film.  
Immunohistochemical (IHC) staining 
Tumors and omental tissues were washed with 
PBS and cut into 1.5 cm × 1.5 cm × 5 mm sections, 
followed by overnight fixation in a 4% paraformald-
ehyde fixative solution (0.4 g paraformaldehyde and 
5×10-6 M NaOH in 10 mL PBS) at 4°C. IHC was carried 
out using anti-GRO-α and anti-IL-8 (Abcam) 
antibodies, and all IHC slides were analyzed by the 
Aperio ScanScope System (Department of Pathology, 
University of Hong Kong). 
Luciferase reporter assay 
NFκB luciferase reporter assay was performed 
using a NFκB luciferase reporter, Renilla luciferase 
plasmids and the Dual-Luciferase® Reporter Assay 
System (Promega, Madison, WI, USA) as described 
previously [10]. 
Cell proliferation and focus formation assays  
Cell proliferation was examined by XTT cell 
proliferation kit (Roche, Basel, Switzerland). For focus 
formation assays, approximately 1000 cells were 
cultured in each well of a six-well plate and incubated 
with different treatments. After incubation at 37°C in 
an incubator with a humidified atmosphere of 5% CO2 
and 95% air for two weeks, colonies were stained with 
crystal violet and counted.  
Soft agar assay  
Soft agar assays were used to determine the 
anchorage-independent growth ability of cancer cells. 
Approximately 2500 cancer cells were embedded in 
0.2% agarose-medium and laid on the top of a 
supporting layer of 1% agarose-medium (without 
FBS) in each well of a six-well plate. 1 mL culture 
medium was added to each well to avoid dryness. 
After three to four weeks, viable colonies containing 
more than 20 cells were counted and photographed 
under a microscope (Nikon ECLIPSE Ti-S) with 4X 
and 200X magnification.  
Matrigel cell migration and invasion assays  
According to the manufacturer’s (Corning, NY, 
USA) instructions, a cell suspension containing 5 × 104 
cells in serum-free medium was added to each insert. 
The medium (500 μL) containing 1% fetal bovine 
serum OCM or chemokines was added to the lower 
chamber as a chemoattractant. After incubation, the 
migrated/invaded cells were stained and counted by 
microscopy.  
Ex vivo colonization assay  
The protocol for the ex vivo culture of the 
omentum was modified from Khan SM et al. In brief, 
omenta were resected from mice and washed with 
PBS. Each specimen was divided into two pieces and 
cultured in DMEM/F12 with 10% FBS. 
Approximately 1 × 105 stable GFP-labeled CXCR2 
knockdown cells or scramble control cells were 
seeded on the respective cultured omentum and 
incubated in an incubator at 37°C with a humidified 
atmosphere of 5% CO2 and 95% air for 2 weeks to 
allow cancer cell colonization. The medium was 
changed every 4 days, and the number of colonies 
were counted under a ZOETM Fluorescence Cell 
Imager (Bio-Rad).  
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In vivo tumorigenicity assay  
To study the effect of CXCR2 on tumor growth in 
vivo, 2 × 106 ovarian cancer CXCR2-/- SKOV3 or 
parental control cells were implanted intraperiton-
eally (i.p.) into four-week-old female CB17/Icr- 
Prkdcscid (SCID) mice in groups of five. To study the 
effect of the CXCR2 inhibitor SB225002 on tumor 
growth in vivo, SKOV3 parental cells (2 × 106 per 
mouse) were intraperitoneally injected into 
four-week-old SCID mice. When palpable tumors 
formed at week two, the experimental group was 
treated once every 2 days by injection of SB225002 (2.5 
mg/kg) in 200 µL carrier solution (10% DMSO). For 
the control group, only PBS was i.p. injected. After 
approximately 45 days, all mice were sacrificed, and 
the distribution and weight of tumor nodules were 
evaluated. The entire animal study was performed 
according to the guidelines approved by The 
Committee on the Use of Live Animals in Teaching 
and Research of The University of Hong Kong 
(CULATR number: 2560-11).  
Data analysis  
All experiments were repeated at least three 
independent times, unless otherwise stated. Values 
are represented as the mean ± SEM, and a two-tailed 
Student’s t-test was used for comparisons. Fisher’s 
exact test (for parametric data) and the Mann– 
Whitney test (for non-parametric data) were used, 
and P ≤ 0.05 was considered statistically significant.  
Results  
Metastatic ovarian cancer cells exhibit higher 
oncogenic induction in OCM  
The omentum is considered a preferential site of 
ovarian cancer metastasis [5, 12, 13], and thus, it was 
of interest to determine whether the omental 
microenvironment specifically modulated ovarian 
tumor cells to promote metastatic cancer cell 
dissemination. To investigate the role of the tumor 
microenvironment in the aggressiveness of ovarian 
cancer cells, a good tumor cell model is needed that 
closely mimics clinical tumor development. 
Considering the limitations of commercial ovarian 
cancer cell lines, primary ovarian cancer cells obtained 
from the omentum or other intraperitoneal organs 
(metastatic) and ovaries (primary cancer cells) were 
used for this study. To this end, four primary cell lines 
were established from two patients’ tumors: 3bU2S8 
and 3bL8O17 were derived from the primary ovary 
tumor tissue and omental tumor tissue, respectively, 
of a 50-year-old patient who was diagnosed with 
ovarian clear cell carcinoma with the International 
Federation of Gynecology and Obstetrics (FIGO) 
Stage 4, Grade 3; Pod7 and Om8 were derived from 
tumor tissue of the pouch of Douglas (POD) and the 
cancerous omental tissue, respectively, of a 
52-year-old patient who was diagnosed with 
high-grade serous ovarian carcinoma with FIGO 
Stage 3b (Fig. 1A). These cells were verified as 
epithelial ovarian cancer (EOC) cells by 
immunofluorescent staining using pan cytokeratin 
(pan-CK), cytokeratin 7 (CK7) and vimentin (Vim) cell 
markers (Fig. 1B) and flow cytometric analysis for 
CA125 expression (data not shown).  
To mimic the effects of the omental 
microenvironment, OCM was established according 
to our laboratory protocol. To investigate the 
differential responses of metastatic and primary 
tumor ovarian cancer cells, both abovementioned 
primary ovarian cancer cell lines, the human ovarian 
cancer cell lines OVCA433, ES-2, OVKATE and 
OVSAHO, and the immortalized ovarian epithelial 
cell line HOSE96 were used for OCM treatment. The 
results showed that OCM could enhance the 
proliferation of all the ovarian cancer cell lines. Pod7, 
Om8, OVCA433, ES-2, OVKATE and OVSAHO cells 
increased from ~20% to 50% compared with their 
controls, whereas there was no significant effect of 
OCM observed in HOSE96 cells (Fig. 1C). OCM also 
promoted cell growth in the primary clear cell 
carcinoma cell line 3bU2S8 but not in its 
corresponding omental metastatic tumor cell line 
3bL8O17 (Fig. 1C). However, soft agar assays 
demonstrated that OCM treatment enhanced not only 
the size but also the number of colonies in 3bU2S8, 
3bL8O17 and ES-2 cells by nearly 39-fold (Fig. 1D). Of 
note, the omental metastatic tumor cell line 3bL8O17 
displayed an ~2-fold higher capacity for colony 
formation than its corresponding primary tumor cell 
line 3bU2S8 (Fig. 1D), indicating that OCM can 
promote the cell proliferation and anchorage 
independence of metastatic ovarian cancer cells. 
Moreover, transwell cell migration assays showed 
that the ~90% increase in cell migration in 3bU2S8, 
3bL8O17 and ES-2 cells compared with untreated 
controls was caused by OCM treatment and that the 
motility of 3bL8O17 cells was even 1.5-fold faster than 
3bU2S8 cells cultured in OCM (Fig. 1E). Transwell 
invasion assays indicated that the number of cells that 
invaded through the Matrigel was increased from 
~40% to 180% in 3bU2S8, 3bL8O17 and ES-2 cells 
treated with OCM and, more importantly, that 
3bL8O17 cells showed a 1.5-fold higher invasion rate 
than 3bU2S8 cells upon OCM treatment (Fig. 1F), 
implying that the OCM augmented the cell growth, 
anchorage-independent cell growth, and cell migrat-
ion and invasion capacities of ovarian cancer cells, 
particularly in highly metastatic ovarian cancer cells.  
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Figure 1. OCM exacerbates the aggressiveness of ovarian cancer cells. (A) Upper, photomicrographs of 3bU2S8 and 3bL8O17 cells respectively isolated from primary 
ovarian tumor tissues and omental tumor tissues of a 50-year-old patient with ovarian clear cell carcinoma. Lower, photomicrographs of Pod7 and Om8 cells correspondingly 
isolated from POD and cancerous omentum tissue of a 52-year-old patient with high-grade serous ovarian carcinoma. Representative images are presented from the above 
experiments at a magnification of 100×. Scale bar = 50 µm. (B) Immunofluorescent verification of the primary ovarian cancer cells as epithelial origin. 3bU2S8, 3bL8O17, Pod7 
and Om8 cells seeded on glass cover slips were methanol-fixed and incubated with primary mouse monoclonal antibodies including anti-pan-CK (pan cytokeratin), anti-CK7 
(cytokeratin 7) and anti-Vim (vimentin), followed by immunofluorescent-staining with Alexa Fluor 488-conjugated secondary rabbit anti-mouse antibody (green). Nuclei of cells 
were counterstained with DAPI (blue). Images were taken at a magnification of 100×. Scale bar = 25 µm. (C) XTT cell proliferation assay demonstrated that OCM promoted cell 
proliferation in all ovarian cancer cell lines employed including OVCA433, ES-2, OVKATE and OVSAHO and most primary tumor cells such as Pod7, Om8 and 3bU2S8 (*P < 0.05 
and ***P < 0.005). (D) Soft-agar assay revealed that OCM enhanced anchorage independent growth ability in primary and omental metastatic tumor cells as well as representative 
ovarian cancer cell line ES-2 (***P < 0.001). Images were taken at a magnification of 100×. Scale bar = 7.5 µm. (E) Transwell migration assay showed that primary cultured tumor 
cells 3bU2S8, 3bL8O17, Pod7 and Om8 and cancer cell line ES-2 with OCM treatment (18 h) resulted in a significant increase in the number of cells penetrating through the 
membrane when compared with their respective controls with 1% FBS normal medium (*P < 0.05 and ***P < 0.001). Scale bar = 50 µm. (F) 3bU2S8, 3bL8O17 and ES-2 cells 
treated with OCM (48 h) displayed more invaded cells through the Matrigel as compared with their respective controls with 1% FBS normal medium (**P < 0.01). Numbers of 
migrated or invaded cells in three randomly chosen fields were counted for three independent experiments and the normalized numerical data are presented in bar charts with 
error bars. Scale bar = 50 µm.  
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OCM activates the TAK1/NFκB signal 
transduction arm in ovarian cancer cells  
Our recent study found that distant metastases 
samples of ovarian cancer patients exhibit a higher 
level of transforming growth factor (TGF)-β- 
activating kinase 1 (TAK1) compared to the primary 
ovarian tumors [10]. Importantly, TAK1 is a 
serine/threonine kinase, and the increase in p-TAK1 
(Ser412) could profoundly activate NFκB activity and 
increase its associated tumor aggressiveness [10, 14]. 
Consistent with our previous findings, western blot 
analysis revealed that the metastatic ovarian cancer 
cell line 3bL8O17 had stronger expression of TAK1 
than 3bU2S8 cells (Fig. 2A). Further study of our cell 
lines and clinical samples showed that the levels of 
both TAK1 and p-TAK1 (Ser412) were significantly 
higher in metastatic cell lines such as Pod7 (metastatic 
cells from the POD, high-grade serous carcinoma, 
Stage 2b), Om8 (metastatic cancer cells from the 
omentum removed from the same patient as Pod7), 
and cancerous omental tissue (HGSC (O), high-grade 
serous carcinoma, Stage 3c and Grade 3) than those in 
the primary tumor tissue (HGSC (P), high-grade 
serous carcinoma, Stage 3c and Grade 3), the primary 
ovarian cancer cell line 3bU2S8 and another primary 
ovarian tumor tissue (EC, endometrioid adeno-
carcinoma, Stage 1c and Grade 2) (Fig. 2B). These 
findings indicate that the metastatic ovarian cancer 
cells intrinsically alter tumor progression to support 
their aggressiveness. 
Next, we determined whether the activation of 
the TAK1/NFκB pathway in primary ovarian cancer 
cells such as 3bU2S8 and 3bL8O17 was induced by 
OCM. The results revealed that OCM treatment 
yielded a marked increase in the phosphorylation of 
TAK1 at Ser412 and the NFκB target IκBα at Ser32 
compared with their respective untreated controls. 
Such OCM-mediated TAK1 activation was 
considerably more apparent in 3bL8O17 cells, as 
evidenced by higher expression levels of p-TAK1 
(Ser412) and p-IκBα (Ser32) when compared with 
those in 3bU2S8 cells (Fig. 2C), suggesting that 
TAK1/NFκB activity was differentially regulated in 
metastatic cells and primary tumor cells upon OCM 
treatment. To further demonstrate that OCM 
enhances the growth of ovarian cancer cells through 
initiation of TAK1/NFκB activity, the 
TAK1 inhibitor (5z)-7-oxozeaenol was 
applied to suppress TAK1 activity. After 
treatment with (5z)-7-oxozeaenol (2.5 
μM), not only was the expression of 
p-TAK1 (Ser412) markedly attenuated but 
also OCM-induced NFκB activity was 
significantly counteracted in ES-2 cells 
compared with the positive control 
treated with only OCM (Fig. 2D). These 
findings support the idea that increased 
TAK1 facilities the activation of the NFκB 
pathway in ovarian cancer, which in turn 
promotes the metastatic progression of 
ovarian cancer cells in OCM.  
GRO-α and IL-8 are the 
predominant chemokines in OCM  
Emerging evidence has suggested 
that chemokines are the dominant factors 
in the tumor microenvironment that 
promote metastatic progression [15-17]. 
To this end, to elucidate the molecular 
mechanisms driving ovarian cancer 
aggressiveness, we analyzed OCM estab-
lished from either a normal (omental 
tissue obtained from a normal female) or 
cancerous omentum (omental tissue 
obtained from an ovarian cancer patient) 
using a human cytokine array. We found 
that the cancerous OCM had more chemo-
kines expressed than the normal OCM 
 
 
Figure 2. OCM induces TAK1/NFκB activation in ovarian cancer cells. (A) Higher 
expression level of TAK1 was observed in omental metastasized ovarian cancer cells, such as 
3bL8O17, as compared with its primary ovarian cancer counterpart cells, such as 3bU2S8. (B) The 
expression levels of p-TAK1 (Ser412) and TAK1 in distant metastatic specimens such as omentum 
(Om8 and HGSC(O) cells) and POD (Pod7 cells) were relatively stronger than those in primary 
ovarian tumor tissues (3bU2S8, EC, and HGSC(P)). (C) Western blot analysis was performed to 
reveal the differential initiation of TAK1/NFκB signalling between primary (3bU2S8 cells) and 
metastatic (3bL8O17 cells) ovarian tumor cells in response to OCM treatment (24 h). (D) A 
TAK-1 inhibitor blocked OCM-mediated phosphorylation on TAK1/NFκB signalling in ES-2 cells. 
Treatment with (5z)-7-oxozeaenol (2.5 μM) reduced Ser412 phosphorylation and NFκB activity 
induced by OCM (24 h). Representative cropped blots are presented.  
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(Fig. 3A). Among these chemokines, GRO-α, IL-8 and 
CXCL7 were commonly found in both types of OCM 
(Fig. 3A), while chemerin, IL-16 and CXCL4 solely 
existed in cancerous OCM (Fig. 3A). As OCM 
activated cancer cell metastasis by mediating NFκB 
activity, we therefore studied the interaction network 
of chemokines and NFκB signaling by bioinformatics 
online software at http://pathwaynet.princeton.edu 
(Fig. 3B). The pathway analysis identified ELR+ CXC 
chemokines GRO-α (CXCL1) and IL-8 as the only 
cytokines that exhibited a strong relationship with 
NFκB regulation (Fig. 3B). On the other hand, CXCL7, 
chemerin and other chemokines, could neither be 
found in the bioinformatics analysis nor activate 
TAK1/NFκB signaling when their recombinant 
proteins were used in ovarian cancer cells (Fig. S1). 
Therefore, we concentrated our attention on the 
expression levels and functional roles of IL-8 and 
GRO-α.  
Given that both IL-8 and GRO-α are the 
predominant players in OCM that are responsible for 
activating TAK1/NFκB signaling and ovarian cancer 
aggressiveness, it is important to quantify their levels 
in OCM obtained from patients. Sixteen normal or 
cancerous omental samples were used to prepare 
OCM. Using human CXCL1/GRO-α and IL-8 ELISA 
assays, the average concentrations of GRO-α and IL-8 
were 9.26 ng/mL and 75 ng/mL respectively in OCM 
(Fig. 3C). After normalizing the dry weights of the 
omental tissues, the concentrations of GRO-α in 
normal and cancerous OCM were calculated as 0.16 ± 
0.06 µg/g and 0.24 ± 0.1 µg/g respectively (Fig. 3D). 
There were no significant changes in the 
concentration of GRO-α (P = 0.56) between normal 
and cancerous OCM (Fig. 3D). On the other hand, the 
concentrations of IL-8 were 0.64 ± 0.16 µg/g and 2.58 ± 
0.66 µg/g in normal and cancerous OCM, respectively 
(Fig. 3D). IL-8 was at a 3-fold higher concentration in 
cancerous OCM when compared with that in normal 
OCM (Fig. 3D). These data indicate that both GRO-α 
and IL-8 are abundantly released from omental 
tissues, whereas IL-8 might be secreted not only by 
the omental tissues but also by cancer cells.  
To examine which tissue types secrete GRO-α 
and IL-8, normal omenta (n = 9), cancerous omenta (n 
= 6) and omentum-metastasized tumors (n = 2) were 
sectioned for IHC staining for GRO-α and IL-8. 
Among normal and cancerous omental sections, four 
tissue types, lymph node, milky spot, blood vessel 
and adipose tissue, preferentially expressed GRO-α 
and IL-8 (Fig. 3E). These chemokines were also found 
in tumor samples, and intriguingly, the expression of 
IL-8 in omentum-metastasized tumor cells was 
extraordinarily high (Fig. 3E), implying that the 
upregulated IL-8 in cancerous OCM potentially comes 
from ovarian metastatic cancer cells. Indeed, QPCR 
analysis revealed that co-treatment of IL-8 could 
induce a positive feedback loop to further elevate IL-8 
but not GRO-α dose dependently in ES-2 and SKOV3 
cells (Fig. 3F and Fig. S2). In contrast, blocking 
CXCR2/TAK1/NFκB signaling by CXCR2 inhibitor 
SB225002 or TAK1 inhibitor (5z)-7-oxozeaenol could 
impair IL-8 positive feedback response (Fig. 3F and 
Fig. S2). These data support the notion that a positive 
feedback loop of IL-8 secretion is bridging between 
tumor cells and cancerous omental tissues. 
GRO-α and IL-8 are capable of enhancing 
cancer cell aggressiveness by activation of the 
TAK/NFκB cascade   
We have shown that OCM can enhance the 
oncogenic properties of ovarian cancer cells. Because 
GRO-α and IL-8 are the predominant chemokines in 
OCM, their functional roles in ovarian cancer cells 
were further examined. The results of XTT cell 
proliferation assays showed that GRO-α (100 ng/mL) 
and IL-8 (25 ng/mL) resulted in the highest 
proliferation rate in OVCA433 cells on day 4 (Fig. 4A), 
while GRO-α (40 ng/mL) and IL-8 (50 ng/mL) 
induced the same cell proliferation rate in A2780cp 
cells (Fig. 4A). This finding indicates that GRO-α and 
IL-8 function similar to OCM in activating the growth 
of human ovarian cancer cells, but there is a 
differential response of ovarian cancer cells to GRO-α 
and IL-8 stimulation. In addition, Transwell cell 
migration assays revealed that there was an ~20% to 
50% increase in ES-2 cell migration caused by IL-8 (50 
ng/mL) or GRO-α (80 ng/mL) treatment compared 
with the untreated control (Fig. 4B). Furthermore, 
transwell invasion assays showed that the number of 
cells that invaded through the Matrigel also increased 
by at least 10% to 30% in ES-2 cells treated with IL-8 
(50 ng/mL) or GRO-α (80 ng/mL). To further confirm 
the functional importance of IL-8 and GRO-α in OCM, 
transwell migration and invasion assays were 
additionally conducted in ES-2 cells through co-treat-
ment of anti-GRO-α, anti-IL-8 or anti-CXCR2 
antibody (2 μg/mL) with OCM. Compared with the 
untreated control, OCM could profoundly enhance 
the migration and invasion capabilities of ES-2 cells 
by 3.8-fold and 1.8-fold respectively. Conversely, the 
OCM-promoted cell migration was reduced to 
~2.5-fold when ES-2 cells were co-treated with 
anti-GRO-α, anti-IL-8 or anti-CXCR2 antibody (Fig. 
4C). Similarly, the OCM-promoted cell invasion in 
ES-2 cells could be inhibited by anti-CXCR2 and 
anti-GRO-α antibodies, but not by anti-IL-8 (Fig. 4D), 
suggesting that both IL-8 and GRO-α function 
separately in OCM to promote the tumorigenicity of 
ovarian cancer. 
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Figure 3. CXC chemokines GRO-α (CXCL1) and IL-8 (CXCL8) are frequently upregulated in OCM. (A) Human cytokine array analysis was carried 
out on normal OCMs (n = 2) and cancerous OCMs (n = 5). The control membrane represented the 1% FBS medium. Among all these chemokines examined, GRO-α, 
IL-8 and CXCL7 were highly expressed in both normal and cancerous OCMs, whereas chemerin, IL-16 and CXCL4 were only released in cancerous OCMs. (B) 
Pathway analysis of transcription factors that potentially interacted with GRO-α (CXCL1) and IL-8 by PathwayNet analysis program. The candidate transcription 
factors with the highest confidence including NFκB are shown in the diagram as purple coloured dots. (C) The concentrations of GRO-α and IL-8 in normal OCMs 
(n = 6) and cancerous OCMs (n = 10) were respectively measured by Human CXCL1/GRO-α DuoSet ELISA and Human IL-8 ELISA. The ranges and mean values of 
concentrations were calculated and plotted. (D) Expression levels of GRO-α and IL-8 were normalized by the corresponding dry mass of omentum tissue employed 
for preparing each OCM sample and grouped into normal or cancerous OCM. (E) IHC analysis was conducted against GRO-α and IL-8 (1: 500) in 15 omental 
specimens including milky spots, lymph nodes, blood vessels and adipose tissues as well as 2 omental metastatic ovarian tumors. Higher expression level of IL-8 was 
observed in ovarian tumor cells metastasized to omentum and representative tumor sample (Ov75, serous adenocarcinoma, Stage 4 and Grade 3 with omental 
metastasis) is presented. (F) QPCR analysis revealed that treatment with IL-8 (25 and 50 ng/mL) for 24 h induced a positive feedback loop in ES-2 cells in a dose 
dependent manner, whereas GRO-α (20, 40 and 80 ng/mL) treatment was unlikely to trigger a similar phenomenon. In addition, the IL-8-induced positive feedback 
was apparently retarded in ES-2 cells when co-treated with IL-8 (50 ng/mL) and SB225002 (5 μM) or (5z)-7-oxozeaenol (2.5 μM) for 24 h. Scale bar = 200 µm. 
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Figure 4. GRO-α and IL-8 are the decisive chemokines in exaggerating ovarian cancer cell aggressiveness via activation of TAK1/NFκB 
signaling. (A) XTT cell proliferation assay demonstrated that GRO-α and IL-8 promoted cell growth in OVCA433 and A2780cp cells as compared with the 
respective controls. Additionally, the growth stimulatory effect was most obvious in OVCA433 cells (*** P < 0.0005) treated with GRO-α (100 ng/mL) and IL-8 (25 
ng/mL) over a time course of 4-days treatment, whereas GRO-α (40 ng/mL) and IL-8 (50 ng/mL) were required to produce a similar effect in A2780cp cells (*** P < 
0.0005). (B) Transwell migration assay showed that ES-2 cells treated with IL-8 (50 ng/mL) and GRO-α (80 ng/mL) for 18 h exhibited a significant upsurge in the 
number of cells penetrating through the membrane as compared with untreated controls (*P < 0.05 and ***P < 0.001). In addition, ES-2 cells treated with same 
conditions of IL-8 and GRO-α showed more invaded cells through the Matrigel as compared with the control (**P < 0.01 and ***P < 0.001). Scale bar = 50 µm. (C) 
Transwell migration assay showed that OCM-mediated migration was significantly inhibited in ES-2 cells when co-treated with anti-GRO-α, anti-IL-8, anti-CXCR2 
antibodies (2 μg/mL) (*P < 0.05) or (5z)-7-oxozeaenol (2.5 μM) (***P < 0.001) for18 h. Scale bar = 50 µm. (D) ES-2 cells co-treated with anti-GRO-α, anti-CXCR2 
antibodies (2 μg/mL) (*P < 0.05) or (5z)-7-oxozeaenol (2.5 μM) (***P < 0.001) showed fewer invaded cells through the Matrigel as compared with the only 
OCM-treated cells. Numbers of migrated or invaded cells in three randomly chosen fields were counted for three independent experiments and the normalized 
numerical data are presented in bar charts with error bars. Scale bar = 50 µm. (E) Western blot analysis demonstrated that treatment with either GRO-α (80 and 100 
ng/mL) or IL-8 (25 and 50 ng/mL) upregulated the TAK/NFκB activity in ES-2 cells as witnessed by the increase in the phosphorylation of TAK1 and its downstream 
targets IKKα/β and IκBα. (F) Co-treatment of antibodies (2 μg/mL) of CXCR2, GRO-α and IL-8 with OCM in ES-2 cells suppressed the promoting effect of OCM on 
TAK/NFκB signalling activity.  
 Theranostics 2018, Vol. 8, Issue 5 
 
 
http://www.thno.org 
1279 
 Considering our previous data that activation of 
the TAK1/NFκB signaling axis augments malignant 
cell migration and cell invasion, it was of paramount 
importance to determine whether blocking TAK1 
activity could attenuate NFκB-mediated cancer cell 
migration and invasion in ovarian cancer. As 
expected, ES-2 cells exhibited a decreased capacity for 
cell migration and cell invasion upon co-treatment of 
TAK1 inhibitor (5z)-7-oxozeaenol (2.5 μM) with OCM 
(P < 0.0001) when compared with OCM only 
treatment (Fig. 4C and D). Mechanistic studies using a 
NFκB luciferase reporter assay in HEK293 cells 
revealed that both IL-8 and GRO-α markedly 
increased NFκB activity (Fig. S3A). Western blot 
analysis further confirmed that both chemokines 
could increase the phosphorylation of TAK1 at Ser412 
and of its downstream targets IKKα/β at Ser180/181 
and IκBα at Ser32 in ES-2 cells when compared with 
the untreated control (Fig. 4E). Conversely, the 
increased expression level of p-TAK1 (Ser412), 
p-IKKα/β (Ser180/181) and p-IκBα (Ser32) in ES-2 
cells was remarkably suppressed by co-treatment of 
anti-GRO-α, anti-IL-8 or anti-CXCR2 antibody (2 
μg/mL) with OCM (Fig. 4F). The inhibition of NFκB 
activity was also proven by a NFκB luciferase reporter 
assay in HEK293 cells (Fig. S3B). Taken together, our 
data indicate that GRO-α and IL-8 may work 
separately to govern ovarian cancer aggressiveness 
but that both are key factors in modulating the 
TAK1/NFκB cascade in ovarian cancer cells.  
CXCR2 is required for IL-8, GRO-α and OCM 
to activate TAK1/NFκB signaling in ovarian 
cancer  
Mounting evidence suggests that CXC 
chemokine receptor 2 (CXCR2) is the common 
receptor of IL-8 and GRO-α in human cancers, 
including in ovarian cancer cells [18, 19]. Aberrant 
upregulation of CXCR2 has been shown to promote 
tumor progression in ovarian cancers [19], indicating 
its importance in ovarian cancer peritoneal 
metastases. By analyzing the expression of CXCR2 in 
ovarian cancer using Kaplan-Meier Plotter (ovarian 
cancer) (http://kmplot.com/analysis/index.php?p= 
service&cancer=ovar), we found that the high 
expression of CXCR2 was significantly correlated 
with lower progression-free survival (PFS) (P = 0.049) 
and post-progression survival (PPS) (P = 0.015) but 
not overall survival (OS) (P = 0.21) (Fig. S4) in ovarian 
cancer. This finding indicates that the upregulated 
CXCR2 might affect ovarian cancer recurrence and 
metastasis, leading to poor PFS and PPS. However, 
there is no significance for GRO-α and IL-8 in patient 
survival (Fig. S4).  
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Figure 5. CXCR2 is required for GRO-α, IL-8 and OCM-mediated TAK/NFκB activation in ovarian cancer cells. (A) Quantitative PCR analysis was 
performed on ES-2 cells transfected with either shCXCR2 plasmid or scrambled control vector (SC). The selected stable clone, shCXCR2-C2, expressed the lowest 
CXCR2 level (*P = 0.04) among all four clones as compared with the SC. (B) Western blot analysis showed that OCM-induced TAK/NFκB activity in the scrambled 
control could be significantly suppressed upon depletion of CXCR2. 1% FBS normal medium was used in the control treatment. (C) XTT cell proliferation assay 
verified that OCM persuaded cell proliferation in ES-2 scrambled control cells (***P < 0.0001) when compared with treatment of 1% FBS normal medium, and such 
growth promotional effect was significantly attenuated upon knockdown of CXCR2 (***P < 0.0001). (D) Soft-agar assay revealed that OCM enhanced anchorage 
independent growth ability in ES-2 scrambled control cells (***P < 0.0001) as compared with treatment of 1% FBS normal medium for 20 days, whereas the 
OCM-initiated anchorage independence was decreased upon knockdown of CXCR2 (*P < 0.05). (E) Transwell migration assay showed that OCM enhanced cell 
migration in ES-2 scrambled control cells (***P < 0.0001) as compared with treatment of 1% FBS normal medium for 18 h, while the OCM-promoted cell migration 
capability was lessened upon silencing of CXCR2 (***P < 0.0001). Scale bar = 50 µm. (F) ES-2 scrambled control cells treated with OCM for 24 h displayed more 
invaded cells through the Matrigel as compared with the respective control with 1% FBS normal medium (***P < 0.0001), and such OCM-stimulated invasive capability 
was lowered in CXCR2-depleted ES-2 cells (***P < 0.0001). Numbers of migrated or invaded cells in three randomly chosen fields were counted for three 
independent experiments and the normalized numerical data are presented in bar charts with error bars. Scale bar = 50 µm. (G) An ex vivo mouse omentum model 
was developed to examine the cancer cell colonization ability upon CXCR2 knockdown. ES-2 shCXCR2-C2 cells and scrambled control cells were labeled with GFP 
using LV-CMV-RLuc-IRES-GFP lentiviral particles and selected by FASC sorting. The chosen GFP-labelled cells were co-cultured with omenta dissected from female 
mice in 10% FBS DMEM/F12 medium for 2 weeks. Fluorescent colonies were counted under a microscope and significant reduction in the number of colonies was 
observed in shCXCR2-C2 (* P= 0.0077) as compared with scrambled control. Representative images are presented from the above experiments at a magnification 
of 40× and arrows indicate the locations of tumor nodules. Scale bar = 100 µm. 
 
To further investigate the role of CXCR2 in 
OCM-mediated ovarian cancer cell aggressiveness, 
CXCR2 was stably knocked down in ES-2 cells by 
shRNAi. The expression of CXCR2 in four selected 
stable CXCR2 knockdown clones was verified by 
QPCR analysis (Fig. 5A). Western blot analysis 
showed that TAK1/NFκB signaling was reduced in 
CXCR2 knockdown clones (shCXCR2-C2) compared 
with the scrambled control, indicating that CXCR2 is 
involved in modulating the NFκB pathway under 
normal conditions (Fig. 5B). However, once ovarian 
cancer cells were cultured in OCM, the levels of 
p-TAK1, p-IKK and p-IκB were highly upregulated in 
the scrambled control, while CXCR2-depleted ovarian 
cancer cells (shCXCR2-C2) only showed no or minor 
effect(s) on the induction of p-TAK1, p-IKK and p-IκB 
(Fig. 5B). This finding suggests that CXCR2 is a crucial 
factor for mediating the roles of IL-8 and GRO-α in the 
activation of TAK1/NFκB signaling. Functionally, 
knockdown of CXCR2 significantly inhibited the cell 
proliferation rate by 33% (P < 0.0001) (Fig. 5C) but did 
not alter the capacities of ovarian cancer cells in 
anchorage-independent growth (P = 0.35) (Fig. 5D), 
migration (P = 0.20) (Fig. 5E), and invasion (P = 0.37) 
(Fig. 5F). In contrast, with OCM treatment, depletion 
of CXCR2 in ES-2 cells (shCXCR2-C2) remarkably 
reduced cell growth by 29% (P < 0.0001) (Fig. 5C), 
anchorage-independent growth by 70% (P<0.0001) 
(Fig. 5D), and cell migration by 120% (P < 0.0001) (Fig. 
5E) compared with the respective scrambled controls. 
However, cell invasion capacity was not affected by 
OCM treatment in the CXCR2 knockdown clone (P = 
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0.09) (Fig. 5F). Moreover, we employed an ex vivo 
mouse omentum model to examine the role of CXCR2 
in ovarian cancer cell colonization. With GFP-labeled 
cells, fluorescence microscopy revealed that 
knockdown of CXCR2 in ES-2 cells significantly 
reduced both the number and size of colonies by 70% 
on the surface of murine omenta (P = 0.0077) (Fig. 5G). 
Collectively, these data suggest that CXCR2 is vital for 
OCM-mediated cancer cell aggressiveness via the 
TAK1/NFκB signaling cascade.  
Targeting of CXCR2 is capable of blocking 
IL-8/GRO-α−induced ovarian cancer 
aggressiveness 
 It is known that reducing the amount of 
chemokine receptors is not enough to block their 
amplification of downstream signaling completely 
[20]. Hence, to better understand the functional role of 
CXCR2 in mediating IL-8 and GRO-α-induced 
activation of TAK1/NFκB signaling, endogenous 
CXCR2 was completely silenced by CRISPR/ 
Cas9-mediated gene knockout (Fig. 6A). Consistently, 
knockout of CXCR2 in ovarian cancer cell lines such 
as SKOV3 cells, strongly reduced the OCM-mediated 
activation of TAK1 and NFκB signaling activities (Fig. 
6B). Similarly, SKOV3 CXCR2-/- cells showed 
increased suppressive effects on focus formation 
(55%; P < 0.05), although there was still a slight 
amount of cell growth (Fig. 6C). In addition, knockout 
of CXCR2 led to a 50% reduction in the cell migration 
and invasion capacities of SKOV3 cells cultured with 
GRO-α/IL-8, 1% FBS control medium or OCM (Fig. 
6D, E and Fig. S5). Noticeably, knockout of CXCR2 
showed a stronger inhibition effect than CXCR2 
knockdown on the cell invasion capacity of SKOV3 
cells (Fig. 6E), indicating that CXCR2 plays a more 
important role in ovarian cancer cell invasiveness. 
Because our ex vivo study showed that CXCR2 is vital 
for ovarian cancer cell colonization of the omentum, it 
was important to examine its effect on in vivo tumor 
dissemination in severe combined immunodeficiency 
(SCID) mice. To this end, SKOV3 CXCR2-/- and 
parental control cells were intraperitoneally injected 
into SCID mice. After 45 days, the mice were 
sacrificed. As expected, knockout of CXCR2 caused 
much less tumor seeding throughout the peritoneal 
cavity of the mice (Fig. 6F). There were 4-fold fewer 
tumor nodules developed with a 3.5-fold lower tumor 
weight in SCID mice grafted with SKOV3 CXCR2-/- 
cells as compared with SCID mice injected with 
SKOV3 parental control cells (Fig. 6F). These findings 
suggest that CXCR2 plays a key role in mediating 
TAK1/NFκB signaling and thus in its associated 
ovarian cancer aggressiveness.  
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Figure 6. Directing therapeutic approaches against CXCR2 is a potential strategy in hindering GRO-α- and IL-8-modulated ovarian cancer 
aggressiveness. (A) Western blot analysis was conducted to check the knockout efficiency of CXCR2 on SKOV3 CXCR2-/- cells and it showed CXCR2 was 
thoroughly depleted by a CRISPR/Cas9 gene-editing approach. (B) Western blot analysis confirmed that SKOV3 CXCR2-/- cells exhibited a much lower activation of 
TAK1/NFκB signalling upon OCM treatment for 24 h when compared with the parental control. (C) Focus formation assay demonstrating a significant escalation of 
the number of colonies formed in SKOV3 parental cells treated with OCM, while apparent inhibition of colony formation occurred in SKOV3 CXCR2-/- cells treated 
with same condition. (D) Transwell migration assay showed that OCM enhanced cell migration in SKOV3 parental cells (*P < 0.01) as compared with treatment of 
1% FBS normal medium for 18 h, while the OCM-promoted cell migration capability was lessened upon complete silencing of CXCR2 (*P < 0.01). Scale bar = 50 µm. 
(E) SKOV3 parental cells treated with OCM for 24 h displayed more invaded cells through the Matrigel as compared with the respective control with 1% FBS normal 
medium (*P < 0.01) and such OCM-stimulated invasive capability was lowered in SKOV3 CXCR2-/- cells (*P < 0.01). Numbers of migrated or invaded cells in three 
randomly chosen fields were counted for three independent experiments and the normalized numerical data are presented in bar charts with error bars. Scale bar 
= 50 µm. (F) Effects of CXCR2 knockout on ovarian tumor dissemination in a xenograft mouse tumor model. Ovarian cancer cell line with stable knockout of CXCR2 
and parental control of SKOV3 cells were i.p. inoculated into 4-week-old female SCID mice. Average tumor burden and the relative number of tumor nodules formed 
by CXCR2 knockout were much lower than in the parental control, which exhibited tumor nodules throughout the peritoneal cavity as photographed on Day 45. The 
yellow arrows indicate the location of tumor nodules in the peritoneal cavity of the mouse. (G) Concentration-dependent inhibition of cell proliferation in SKOV3 
cells (* P ≤ 0.005) treated with SB225002 (0.625, 1.25, 2.5 and 5 μM) for 2 days was revealed using XTT cell proliferation assay. (H) Western blot analysis confirmed 
that TAK1/NFκB signaling was inhibited dose-dependently in SKOV3 cells upon treatment with SB225002 (1.25 and 2.5 μM) as compared with untreated control. (I) 
Upper, a schematic presentation of the experimental set-up. Lower, effects of CXCR2 inhibitor on ovarian tumor dissemination in a xenograft mouse tumor model. 
SKOV3 cells were i.p. inoculated into 4-week-old female SCID mice. On Day 14 post-injection of tumor cells, treatment with SB225002 (2.5 mg/kg) was initiated and 
carried out every 2 days with a total of 15 injections. Average tumor burden and number of tumor nodules formed by CXCR2 inhibition were much lower than in 
the PBS-treated control, which exhibited tumor nodules throughout the peritoneal cavity as photographed on Day 45. The yellow arrows indicate the locations of 
tumor nodules in the peritoneal cavity of the mouse. (J) Western blot analysis verified that TAK1/NFκB signalling was inhibited in xenograft tumor tissues of the 
SB225002-treated group. 
 
Given that depletion of CXCR2 could effectively 
impair IL-8 or GRO-α-mediated TAK1/NFκB 
signaling and ovarian cancer aggressiveness, it was of 
great importance to investigate any CXCR2 inhibitors 
that could be used as effective treatments for 
controlling the peritoneal metastases of ovarian 
cancer. Therefore, we investigated the efficiency and 
feasibility of a selective non-peptide CXCR2 
antagonist, SB225002, to block the functions of CXCR2 
in ovarian cancer cells. By XTT cell proliferation assay, 
we showed that SB225002 could significantly inhibit 
the cell viability of SKOV3 cells in a dose-dependent 
manner (Fig. 6G). Of note, a low dose of SB225002 
(0.625 µM) was equivalent to the effects of CXCR2 
knockout and resulted in ~58% reduction in the cell 
viability of SKOV3 cells for 2 days (Fig. 6C and G), 
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indicating that SB225002 is a potent CXCR2 inhibitor. 
Correspondingly, western blot analysis revealed that 
SB225002 could strongly suppress TAK1 and NFκB 
activities, similar to that observed in SKOV3 CXCR2-/- 
cells (Fig. 6B and H). Moreover, to gain deeper 
insights into the functional effect of SB225002 on 
tumor seeding in the peritoneal cavity, SKOV3 cells 
were intraperitoneally xenografted into SCID mice. 
When palpable tumors formed on Day 14, SB225002 
(2.5 mg/kg) in carrier solution was intraperitoneally 
administered into tumor-bearing mice once every 2 
days with a total of 15 injections before all mice were 
sacrificed (Fig. 6I). Consistent with the findings 
regarding SKOV3 CXCR2-/- tumor growth in mice, we 
found that SB225002 could remarkably inhibit tumor 
seeding and tumor growth in the peritoneal cavity of 
SCID mice as evidenced by the ~45% reduction in 
tumor weight and the ~50% decrease in the number of 
tumor nodules formed (Fig. 6I). Western blot analysis 
also confirmed that tumor tissues from the 
SB225002-treated group exhibited reduction of TAK1 
and NFκB signaling activities as compared with the 
control group (Fig. 6J). However, compared with 
SKOV3 CXCR2-/-, SB225002 treatment mainly 
inhibited metastatic spreading to the peritoneum 
instead of strongly reducing primary tumor growth 
(Fig. 6I). This different effect might be due to the 
limited diffusion of SB225002 into the inner portions 
of primary tumors. Nevertheless, these findings still 
indicate that SB225002 functions similar to the effects 
of CXCR2 knockout in ovarian cancer cells. Hence, 
SB225002 may be applied as an effective remedy to 
impair tumor dissemination in ovarian cancer.  
Discussion  
Clinical observations have shown that ovarian 
cancer accompanied with peritoneal metastases 
usually indicates a very poor prognosis [21]. 
Emerging evidence suggests that malignant ascites act 
as a reservoir, providing plenty of fatty acids, soluble 
growth factors and chemokines for use in remodeling 
shed ovarian cancer cells to more aggressive 
metastatic cancer cells [4, 22, 23]. In this study, we 
showed that OCM mimics the tumor 
microenvironment of the human omentum in 
promoting ovarian cancer cell aggressiveness and that 
omental-metastasized ovarian cancer cells per se 
behave more aggressively via activation of 
TAK1/NFκB signaling. Notably, we are the first to 
report that GRO-α and IL-8 released from normal and 
cancerous omenta are the key chemokines that 
activate TAK1/NFκB signaling and promote ovarian 
cancer seeding and growth in the peritoneal cavity via 
CXCR2. Therefore, targeting CXCR2 by genetic or 
pharmaceutical approaches could be promising 
therapeutic regimes for impeding ovarian cancer 
peritoneal metastases.  
Previous studies have suggested that TGF-β 
signaling is initiated in cancer metastasis, indicating 
that this signaling is one of the potential therapeutic 
targets for combating ovarian cancer peritoneal 
metastases [24-26]. TGF-β-activated kinase 1 (TAK1) 
is a serine/threonine kinase and is frequently 
upregulated in ovarian cancer cells and clinical 
samples accompanied with high-grade and distant 
metastasized tumors [10]. The phosphorylation of 
TAK1 at serine 412 promotes cell proliferation, 
migration and invasion by activating NFκB signaling 
in ovarian cancer cells [10]. Coincidently, in the 
present study, higher TAK1/NFκB signaling was seen 
in metastatic ovarian cancer cells upon treatment with 
OCM, and the magnitude of enhanced signaling 
activity was proportional to the aggressiveness of the 
ovarian cancer cells. On the other hand, it is known 
that the aberrant activation of IKKβ/NFκB signaling 
triggers malignant cells to produce cytokines such as 
IL-6, IL-8 and GRO-α [27-29]. These chemokines are 
strongly associated with decreased cell mobility, 
angiogenesis and chemoresistance of human cancers 
[8, 29-32]. Likewise, our results using ELISA and IHC 
analyses illustrated that omentum-metastasized 
tumor cells intrinsically express an enriched array of 
chemokines, thereby implicating the potential of a 
positive feedback loop between these cytokines and 
TAK1/NFκB activity during metastatic progression in 
the peritoneal cavity.  
Accumulating evidence has shown that the 
omentum is the preferential site for peritoneal 
metastasis of ovarian cancer cells [5, 12, 13]. Indeed, a 
wide spectrum of cells and tissues in the omentum 
have been reported to be crucial for this metastatic 
process [5, 33-35]. For instance, cancer-associated 
fibroblasts (CAFs) in the omentum interact with 
ovarian cancer cells to facilitate omental metastasis 
[35, 36]. Adipocytes near ovarian cancer cells are 
thought to provide CAFs with fatty acids and 
chemokines, supporting the growth and propagation 
of the tumors [4, 37]. Herein, our findings revealed 
that chemokines GRO-α and IL-8 are highly expressed 
in omental milky spots, lymph nodes, adipose tissue 
and blood vessels, which supports the idea that these 
tissue types of the omentum determine the 
dissemination of ovarian cancer cells. Moreover, 
GRO-α and IL-8 are detected in both the ascites and 
sera of ovarian cancer patients [38-42], wherein ascites 
intriguingly have a higher level of these chemokines 
than the respective serum samples from the same 
patients. This finding supports our data that GRO-α 
and IL-8 originate from both the omental tissues and 
cancer cells to attract ovarian cancer cell colonization.  
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Previous studies have documented that 
overexpression of G-protein-coupled receptors 
(GPCRs) such as CXCR2 is associated with poor 
prognosis and cancer metastasis in human cancers, 
including in epithelial ovarian cancer [43-45]. 
Kaplan-Meier analysis in this study consistently 
revealed that the high CXCR2 level was inversely 
correlated with progression-free and post-progression 
survival rates, suggesting that CXCR2 exerts 
substantial influences on the recurrence and 
metastasis of ovarian cancer. Notably, CXCR2 has also 
been reported to promote tumor progression in 
ovarian cancer by promoting angiogenesis, 
stimulating cell growth and inhibiting cell death 
through the EGFR/AKT/NFκB pathway [19, 43]. 
Apart from CXCR2, its relevant chemokines, such as 
IL-8, further enhance CXCR2-mediated cancer cell 
metastasis [46, 47]. The pro-angiogenic chemokine 
GRO-α, on the other hand, has been shown to mediate 
the activation of anti-apoptotic pathways in cancer 
cells by interacting with CXCR2 [48, 49]. However, 
GRO-α is also known to increase the oncogenic 
capacities of cancer invasion and migration [18]. 
Herein, we reported that IL-8 and GRO-α display 
functional effects similar to OCM in ovarian cancer 
cells, and in particular, GRO-α was highly expressed 
in normal OCM, suggesting that this is why shed 
ovarian cancer cells tend to preferentially metastasize 
to the omentum [2]. On the other hand, suppressing 
the functions of IL-8 and GRO-α in OCM via 
neutralizing antibodies attenuated OCM-induced cell 
proliferation and cell aggressiveness as well as 
TAK1/NFκB signaling activities, further highlighting 
the importance of these OCM chemokines in 
promoting ovarian cancer aggressiveness. In fact, 
CXCR2 plays a key role in mediating TAK1/NFκB 
signaling after stimulation by either IL-8 or GRO-α. 
Therefore, targeting CXCR2 could achieve useful 
therapeutic effects on ovarian cancer metastasis. As 
expected, our experiments inhibiting CXCR2 function 
by using neutralizing antibodies, shRNA-mediated 
gene knockdown or gene knockout strategies have 
clearly established the crucial role of CXCR2 in the 
activation of TAK1/NFκB signaling in the oncogenic 
capacities of ovarian cancer cells. Similarly, inhibition 
of CXCR2 by SB225002 effectively impeded 
CXCR2-mediated ovarian cancer metastasis in vivo 
has been reported in other human cancer studies [45, 
50], suggesting that this type of CXCR2 antagonist 
could be developed as a potential therapeutic drug for 
preventing peritoneal metastases. 
In summary, this study suggests that IL-8 and 
GRO-α in OCM and the omental tumor 
microenvironment are essential for promoting 
ovarian cancer aggressiveness through activation of 
the CXCR2/TAK1/NFκB signaling axis. Our findings 
underscore the relevance of the tumor 
microenvironment in facilitating ovarian cancer 
metastatic progression and aid in the exploration of 
CXCR2 as a potential therapeutic target for ovarian 
cancer.  
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